Explore
Trendline
Syneron Bio Secures $150 Million to Advance Macrocyclic Peptide Research
Syneron Bio Secures $150 Million to Advance Macrocyclic Peptide Research
Read More
Trendline
Syneron Secures $150 Million to Advance Macrocyclic Peptide Development
Syneron Secures $150 Million to Advance Macrocyclic Peptide Development
Read More
Trendline
Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions
Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions
Read More
Trendline
Stoke Therapeutics to Present at Needham Virtual Healthcare Conference
Stoke Therapeutics to Present at Needham Virtual Healthcare Conference
Read More
Trendline
Viking Therapeutics to Engage with Investors at Upcoming Conferences
Viking Therapeutics to Engage with Investors at Upcoming Conferences
Read More
Trendline
Avalyn Pharma Plans IPO to Advance Inhaled Lung Disease Therapies
Avalyn Pharma Plans IPO to Advance Inhaled Lung Disease Therapies
Read More
Trendline
Biotech Company Immunai Develops AI-Powered Immune Atlas to Enhance Drug Efficacy
Biotech Company Immunai Develops AI-Powered Immune Atlas to Enhance Drug Efficacy
Read More
Trendline
Scala Biodesign Secures $16M to Expand AI-Driven Protein Development
Scala Biodesign Secures $16M to Expand AI-Driven Protein Development
Read More
Trendline
AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials
AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials
Read More
Trendline
Gilead Sciences Shifts Focus to Integration After Series of Acquisitions
Gilead Sciences Shifts Focus to Integration After Series of Acquisitions
Read More
Trendline
Biotech Company Scala Biodesign Secures $16M to Expand AI-Driven Protein Development
Biotech Company Scala Biodesign Secures $16M to Expand AI-Driven Protein Development
Read More
Trendline
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances
Read More